<DOC>
	<DOCNO>NCT00227539</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , positron emission tomography ( PET ) , ( do , , chemotherapy ) may help doctor predict patient 's response treatment help plan best treatment . Drugs use chemotherapy , pemetrexed disodium cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving combination chemotherapy surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study well PET work predict response patient undergoing treatment pemetrexed disodium cisplatin without surgery stage I , stage II , stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Positron Emission Tomography Predicting Response Patients Who Are Undergoing Treatment With Pemetrexed Disodium Cisplatin With Without Surgery Stage I , Stage II , Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine effectiveness fludeoxyglucose F 18 positron emission tomography predict radiological pathological response patient treat pemetrexed disodium cisplatin without surgery stage IB-IIIB non-small cell lung cancer ( NSCLC ) . Secondary - Determine safety cisplatin pemetrexed disodium patient . - Determine radiographic response rate , duration response , time progression patient treat cisplatin pemetrexed disodium . OUTLINE : This multicenter study . - Fludeoxyglucose F 18 ( 18FDG ) positron emission tomography ( PET ) imaging : All patient undergo positron emission tomography ( PET ) image head , neck , thorax , abdomen , pelvis . Patients receive fludeoxyglucose F 18 ( ^18FDG ) IV follow 45 minute rest . PET image do 1 hour 8 minute . Patients undergo PET image three point study : 4 week prior treatment , first cycle treatment , 3 course chemotherapy . Some patient undergo surgical resection tumor . - Chemotherapy : Patients receive cisplatin IV 30 minute pemetrexed disodium IV 10 minute day 1 . Courses repeat every 21 day 3 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 35 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Stage IB , II , IIIA , IIIB ( T4 , N01 ) disease Staging must perform 4 week prior study entry CT scan chest , upper abdomen , fludeoxyglucose F 18 ( ^18FDG ) positron emission tomography ( PET ) scan Mediastinal evaluation stag base combination CT scan FDGPET result If N1 N2 nod find FDGPET CT scan , metastasis must rule brain MRI Measurable resectable disease T4 lesion must resectable Eligible curative surgery No malignant pleural effusion PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,250/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 3.0 time ULN Renal Creatinine clearance ≥ 45 mL/min Pulmonary Adequate pulmonary reserve undergo surgery Predicted FEV_1 &gt; 0.8 L resection Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment Able take corticosteroid Able take folic acid vitamin B_12 supplement No malignancy within past 5 year except nonmelanoma skin cancer noninvasive cervical cancer No concurrent serious uncontrolled disorder would preclude study participation No type I diabetes mellitus Type II diabetes mellitus allow glucose 80150 mg/dL PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy No concurrent prophylactic filgrastim ( GCSF ) No concurrent thrombopoiesisstimulating agent Chemotherapy At least 5 year since prior chemotherapy Endocrine therapy No concurrent anticancer hormonal therapy Radiotherapy No prior radiotherapy chest No concurrent curative palliative radiotherapy Surgery Not specify Other At least 30 day since prior nonFDAapproved investigational agent At least 5 day since prior aspirin nonsteroidal antiinflammatory agent ( 8 day longacting agent [ e.g. , piroxicam ] ) No concurrent anticancer therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>